JP2012528178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528178A5 JP2012528178A5 JP2012513209A JP2012513209A JP2012528178A5 JP 2012528178 A5 JP2012528178 A5 JP 2012528178A5 JP 2012513209 A JP2012513209 A JP 2012513209A JP 2012513209 A JP2012513209 A JP 2012513209A JP 2012528178 A5 JP2012528178 A5 JP 2012528178A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridin
- yloxy
- sulfonyl
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C (O) OH Inorganic materials 0.000 claims description 653
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 125000003342 alkenyl group Chemical group 0.000 claims description 23
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 216
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 193
- 150000001925 cycloalkenes Chemical class 0.000 claims 74
- 150000002390 heteroarenes Chemical class 0.000 claims 74
- 150000001924 cycloalkanes Chemical class 0.000 claims 73
- 150000001875 compounds Chemical class 0.000 claims 57
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 36
- 150000003839 salts Chemical class 0.000 claims 31
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 26
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 125000000304 alkynyl group Chemical group 0.000 claims 20
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- TYERRNIXCPPQQD-UHFFFAOYSA-N N-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C(C1=CC=CC=C1)(=O)NOC=1C=C2C(=NC=1)NC=C2 TYERRNIXCPPQQD-UHFFFAOYSA-N 0.000 claims 10
- WKULGVVLSQGJTK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCC(C)(O)CC1 WKULGVVLSQGJTK-UHFFFAOYSA-N 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 125000004957 naphthylene group Chemical group 0.000 claims 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 5
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000006491 bone marrow cancer Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 125000005549 heteroarylene group Chemical group 0.000 claims 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000025113 myeloid leukemia Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 201000002471 spleen cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- HGCQJSCVVNLDMQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[(4-ethyl-4-hydroxycyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1CC(CC)(O)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1[N+]([O-])=O HGCQJSCVVNLDMQ-UHFFFAOYSA-N 0.000 claims 2
- NKITUFNNDFPWII-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N1CCOCC1 NKITUFNNDFPWII-UHFFFAOYSA-N 0.000 claims 2
- RYUKEAYYUZJDNE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[6-[(4-hydroxy-4-methylcyclohexyl)methylamino]-5-nitropyridin-3-yl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CN=C1NCC1CCC(C)(O)CC1 RYUKEAYYUZJDNE-UHFFFAOYSA-N 0.000 claims 2
- ADTUYXRNYHDWMP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OCC1CCC(C)(O)CC1 ADTUYXRNYHDWMP-UHFFFAOYSA-N 0.000 claims 2
- BEABEHQNCJQGIZ-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6,6-dimethyl-2,5-dihydropyran-3-yl]methyl]piperazin-1-yl]-N-[4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1OC(C)(C)CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N1CCOCC1 BEABEHQNCJQGIZ-UHFFFAOYSA-N 0.000 claims 2
- PXMGHKWJLJTPIN-UHFFFAOYSA-N N-[5-chloro-6-[(1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1OCC1(F)CCC(C)(O)CC1 PXMGHKWJLJTPIN-UHFFFAOYSA-N 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 2
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000005724 cycloalkenylene group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- UQJOQWQMMPNGKT-UHFFFAOYSA-N n-[5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1CC(OC)CCC1COC1=NC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1Cl UQJOQWQMMPNGKT-UHFFFAOYSA-N 0.000 claims 2
- BESVQSQTRRTQCW-WEWYDHJMSA-N n-[5-chloro-6-[[(1r,2r,4r,5s)-2-hydroxy-2-methyl-5-bicyclo[2.2.1]heptanyl]methoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C([C@H]1C[C@H]2C[C@@H]1C[C@]2(O)C)OC(C(=C1)Cl)=NC=C1S(=O)(=O)NC(=O)C(C(=C1)OC=2C=C3C=CNC3=NC=2)=CC=C1N(CC1)CCN1CC(CCC(C)(C)C1)=C1C1=CC=C(Cl)C=C1 BESVQSQTRRTQCW-WEWYDHJMSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 2
- JGIWGFDASVPCTP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-[[4-(oxan-4-ylamino)cyclohexyl]amino]phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1NC1CCOCC1 JGIWGFDASVPCTP-UHFFFAOYSA-N 0.000 claims 1
- JNEYAGUMKHBOPX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-(4-morpholin-4-ylcyclohexyl)oxy-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OC(CC1)CCC1N1CCOCC1 JNEYAGUMKHBOPX-UHFFFAOYSA-N 0.000 claims 1
- FUGPWHUMYNZEGE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1CC(OC)CCC1COC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1[N+]([O-])=O FUGPWHUMYNZEGE-UHFFFAOYSA-N 0.000 claims 1
- PBWXDNYODFLHSA-ZCXBXHLPSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(1R,4R,5R,6S)-5,6-dihydroxy-2-bicyclo[2.2.1]heptanyl]methoxy]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=NC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(OCC4[C@H]5C[C@H]([C@H]([C@H]5O)O)C4)=CC=3)[N+]([O-])=O)=CC=2)=C1C1=CC=C(Cl)C=C1 PBWXDNYODFLHSA-ZCXBXHLPSA-N 0.000 claims 1
- PBWXDNYODFLHSA-WSVPCWEKSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(1R,4R,5S,6R)-5,6-dihydroxy-2-bicyclo[2.2.1]heptanyl]methoxy]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=NC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(OCC4[C@H]5C[C@H]([C@@H]([C@@H]5O)O)C4)=CC=3)[N+]([O-])=O)=CC=2)=C1C1=CC=C(Cl)C=C1 PBWXDNYODFLHSA-WSVPCWEKSA-N 0.000 claims 1
- FODFFPZUZIECRM-MLZZNZMKSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(1S,3R)-3-morpholin-4-ylcyclopentyl]methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound N1([C@@H]2CC[C@@H](C2)CNC2=CC=C(C=C2[N+]([O-])=O)S(=O)(=O)NC(=O)C2=CC=C(C=C2OC=2C=C3C=CNC3=NC=2)N2CCN(CC2)CC=2CCC(CC=2C=2C=CC(Cl)=CC=2)(C)C)CCOCC1 FODFFPZUZIECRM-MLZZNZMKSA-N 0.000 claims 1
- PKOJKTGPUOKMCZ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[4-(cyclopropylamino)cyclohexyl]amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1NC1CC1 PKOJKTGPUOKMCZ-UHFFFAOYSA-N 0.000 claims 1
- XCEYFIPGAZZSPS-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[4-(dicyclopropylamino)cyclohexyl]amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N(C1CC1)C1CC1 XCEYFIPGAZZSPS-UHFFFAOYSA-N 0.000 claims 1
- CZWPSARPAPGCSA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[4-(methanesulfonamido)cyclohexyl]amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCC(NS(C)(=O)=O)CC1 CZWPSARPAPGCSA-UHFFFAOYSA-N 0.000 claims 1
- KNVQPTSRJUELFP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[4-[2-cyanoethyl(cyclopropyl)amino]cyclohexyl]amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N(CCC#N)C1CC1 KNVQPTSRJUELFP-UHFFFAOYSA-N 0.000 claims 1
- IKEXGKFRVMUBDL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-[(1-propan-2-ylpiperidin-4-yl)amino]phenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1CN(C(C)C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1[N+]([O-])=O IKEXGKFRVMUBDL-UHFFFAOYSA-N 0.000 claims 1
- TZAYFMBZFWSUCQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[1-(oxan-4-yl)azetidin-3-yl]amino]phenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(C1)CN1C1CCOCC1 TZAYFMBZFWSUCQ-UHFFFAOYSA-N 0.000 claims 1
- BRQXNCXWHXCDPA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-hydroxy-1-adamantyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=NC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(NCC45CC6CC(CC(C6O)C5)C4)=CC=3)[N+]([O-])=O)=CC=2)=C1C1=CC=C(Cl)C=C1 BRQXNCXWHXCDPA-UHFFFAOYSA-N 0.000 claims 1
- ZLPJPQQDLYGOTP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-methoxyphenyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1=CC(OC)=CC=C1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1[N+]([O-])=O ZLPJPQQDLYGOTP-UHFFFAOYSA-N 0.000 claims 1
- JWICLIKRPNQLLC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(cyclopropylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCNC1CC1 JWICLIKRPNQLLC-UHFFFAOYSA-N 0.000 claims 1
- UDUHXXIMBIIODO-UYHPJTEGSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(1r,3s)-3-hydroxycyclopentyl]methylamino]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC[C@@H]1CC[C@H](O)C1 UDUHXXIMBIIODO-UYHPJTEGSA-N 0.000 claims 1
- UDUHXXIMBIIODO-WHMAPKLYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(1s,3r)-3-hydroxycyclopentyl]methylamino]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC[C@H]1CC[C@@H](O)C1 UDUHXXIMBIIODO-WHMAPKLYSA-N 0.000 claims 1
- QUEPNEUDQZDVFB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[5-cyano-6-[(4-morpholin-4-ylcyclohexyl)amino]pyridin-3-yl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1C#N)=CN=C1NC(CC1)CCC1N1CCOCC1 QUEPNEUDQZDVFB-UHFFFAOYSA-N 0.000 claims 1
- XBANGVMCIRMPAC-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6,6-dimethyl-2,5-dihydropyran-3-yl]methyl]piperazin-1-yl]-N-[4-[(4-morpholin-4-ylcyclohexyl)amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1OC(C)(C)CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1S(=O)(=O)C(F)(F)F)=CC=C1NC(CC1)CCC1N1CCOCC1 XBANGVMCIRMPAC-UHFFFAOYSA-N 0.000 claims 1
- HSIPILLOKFOTJP-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6,6-dimethyl-2,5-dihydropyran-3-yl]methyl]piperazin-1-yl]-n-[4-[(4-methoxycyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1CC(OC)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3COC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1[N+]([O-])=O HSIPILLOKFOTJP-UHFFFAOYSA-N 0.000 claims 1
- OVDYVCQUVWIKBD-UHFFFAOYSA-N 4-[4-[[8-(4-chlorophenyl)spiro[4.5]dec-8-en-9-yl]methyl]piperazin-1-yl]-N-[4-[(4-methoxycyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1CC(OC)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CC4(CCCC4)CCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1[N+]([O-])=O OVDYVCQUVWIKBD-UHFFFAOYSA-N 0.000 claims 1
- KQHBVBJHHZFRTR-UHFFFAOYSA-N 4-[4-[[8-(4-chlorophenyl)spiro[4.5]dec-8-en-9-yl]methyl]piperazin-1-yl]-N-[4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CC4(CCCC4)CCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)=CC=C1NC(CC1)CCC1N1CCOCC1 KQHBVBJHHZFRTR-UHFFFAOYSA-N 0.000 claims 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- ZYUZLEUJKZZXNN-UHFFFAOYSA-N C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 Chemical group C1=CC(CC(N)C(O)=O)=CC=C1OS(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 ZYUZLEUJKZZXNN-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- WBWGIQPTCQYYQV-UHFFFAOYSA-N N-[3-chloro-4-[(4-hydroxy-4-methylcyclohexyl)methoxy]phenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CC=C1OCC1CCC(C)(O)CC1 WBWGIQPTCQYYQV-UHFFFAOYSA-N 0.000 claims 1
- GHGQHMWYLJSPHL-UHFFFAOYSA-N N-[4-[[4-[bis(cyclopropylmethyl)amino]cyclohexyl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N(CC1CC1)CC1CC1 GHGQHMWYLJSPHL-UHFFFAOYSA-N 0.000 claims 1
- HAPIOUDNCDBOIB-UHFFFAOYSA-N N-[5-chloro-6-[(1-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1OCC1(F)CCC(O)CC1 HAPIOUDNCDBOIB-UHFFFAOYSA-N 0.000 claims 1
- JHPHSPYSBGEZFM-UHFFFAOYSA-N N-[5-chloro-6-[(4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1OCC1CCC(C)(O)CC1 JHPHSPYSBGEZFM-UHFFFAOYSA-N 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- LNOQURRKNJKKBU-UHFFFAOYSA-N ethyl piperazine-1-carboxylate Chemical compound CCOC(=O)N1CCNCC1 LNOQURRKNJKKBU-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- RUOFPZZZJJMSAM-GKAZCMFASA-N n-[4-[[(1s,4s)-5-bicyclo[2.2.1]hept-2-enyl]methoxy]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=NC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(OCC4[C@H]5C[C@H](C=C5)C4)=CC=3)[N+]([O-])=O)=CC=2)=C1C1=CC=C(Cl)C=C1 RUOFPZZZJJMSAM-GKAZCMFASA-N 0.000 claims 1
- RAZGFHDBOJFDAQ-UHFFFAOYSA-N n-[4-[[4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzoyl]sulfamoyl]-2-nitrophenyl]morpholine-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(=O)N1CCOCC1 RAZGFHDBOJFDAQ-UHFFFAOYSA-N 0.000 claims 1
- GCHGWBYYMDDACZ-UHFFFAOYSA-N n-[5-chloro-6-[(4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl]sulfonyl-4-[4-[[7-(4-chlorophenyl)spiro[2.5]oct-6-en-6-yl]methyl]piperazin-1-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1CC(C)(O)CCC1COC1=NC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC4(CC4)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=NC=2)C=C1Cl GCHGWBYYMDDACZ-UHFFFAOYSA-N 0.000 claims 1
- BESVQSQTRRTQCW-JTXHSZDZSA-N n-[5-chloro-6-[[(1r,2r,4r,5r)-2-hydroxy-2-methyl-5-bicyclo[2.2.1]heptanyl]methoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C([C@@H]1C[C@H]2C[C@@H]1C[C@]2(O)C)OC(C(=C1)Cl)=NC=C1S(=O)(=O)NC(=O)C(C(=C1)OC=2C=C3C=CNC3=NC=2)=CC=C1N(CC1)CCN1CC(CCC(C)(C)C1)=C1C1=CC=C(Cl)C=C1 BESVQSQTRRTQCW-JTXHSZDZSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18120309P | 2009-05-26 | 2009-05-26 | |
| US61/181,203 | 2009-05-26 | ||
| PCT/US2010/036198 WO2010138588A2 (en) | 2009-05-26 | 2010-05-26 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015003098A Division JP6038195B2 (ja) | 2009-05-26 | 2015-01-09 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528178A JP2012528178A (ja) | 2012-11-12 |
| JP2012528178A5 true JP2012528178A5 (OSRAM) | 2013-08-15 |
| JP5747025B2 JP5747025B2 (ja) | 2015-07-08 |
Family
ID=42677657
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513209A Active JP5747025B2 (ja) | 2009-05-26 | 2010-05-26 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2015003098A Active JP6038195B2 (ja) | 2009-05-26 | 2015-01-09 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2016212548A Active JP6353506B2 (ja) | 2009-05-26 | 2016-10-31 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2018079598A Ceased JP2018138577A (ja) | 2009-05-26 | 2018-04-18 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2019189974A Ceased JP2020023545A (ja) | 2009-05-26 | 2019-10-17 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2021199837A Ceased JP2022033939A (ja) | 2009-05-26 | 2021-12-09 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2023001499A Pending JP2023040165A (ja) | 2009-05-26 | 2023-01-10 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2025019817A Pending JP2025072583A (ja) | 2009-05-26 | 2025-02-10 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015003098A Active JP6038195B2 (ja) | 2009-05-26 | 2015-01-09 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2016212548A Active JP6353506B2 (ja) | 2009-05-26 | 2016-10-31 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2018079598A Ceased JP2018138577A (ja) | 2009-05-26 | 2018-04-18 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2019189974A Ceased JP2020023545A (ja) | 2009-05-26 | 2019-10-17 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2021199837A Ceased JP2022033939A (ja) | 2009-05-26 | 2021-12-09 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2023001499A Pending JP2023040165A (ja) | 2009-05-26 | 2023-01-10 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| JP2025019817A Pending JP2025072583A (ja) | 2009-05-26 | 2025-02-10 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
Country Status (43)
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2376480B1 (en) * | 2008-12-05 | 2016-06-01 | AbbVie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| ES2536090T3 (es) * | 2009-01-19 | 2015-05-20 | Abbvie Inc. | Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunitarias y autoinmunitarias |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| BR122019016429B1 (pt) * | 2009-05-26 | 2020-03-24 | Abbvie Ireland Unlimited Company | Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| ES2699205T3 (es) * | 2010-10-29 | 2019-02-07 | Abbvie Inc | Dispersiones sólidas que contienen un agente que induce la apoptosis |
| UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| AU2011332043C1 (en) | 2010-11-23 | 2016-11-10 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
| NZ708508A (en) | 2010-11-23 | 2016-06-24 | Abbvie Bahamas Ltd | Methods of treatment using selective bcl-2 inhibitors |
| CN104557646B (zh) | 2011-02-15 | 2017-08-29 | 宇部兴产株式会社 | 生产芳基硫五氟化物的工业方法 |
| CN102241649A (zh) * | 2011-07-08 | 2011-11-16 | 陈飞 | 3-四氢呋喃甲醇的制备方法 |
| CN103958508B (zh) | 2011-10-14 | 2019-02-12 | 艾伯维公司 | 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂 |
| WO2013185202A1 (en) * | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| WO2014018567A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| JP6225187B2 (ja) * | 2012-08-13 | 2017-11-01 | アッヴィ・インコーポレイテッド | アポトーシス誘発剤 |
| CN111481552A (zh) | 2012-09-07 | 2020-08-04 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
| LT6064B (lt) | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai |
| LT2914296T (lt) | 2012-11-01 | 2018-09-25 | Infinity Pharmaceuticals, Inc. | Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius |
| US20150283142A1 (en) * | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| AR095265A1 (es) | 2013-03-13 | 2015-09-30 | Abbvie Inc | Procesos para la preparación de un agente inductor de la apoptosis |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| BR112015025711A8 (pt) * | 2013-04-08 | 2019-12-17 | Janssen Pharmaceutica Nv | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer |
| TWI594975B (zh) | 2013-04-24 | 2017-08-11 | 第一三共股份有限公司 | 二羧酸化合物 |
| US9238652B2 (en) | 2014-03-04 | 2016-01-19 | Abbvie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| EP3708170A1 (en) | 2014-05-05 | 2020-09-16 | BioVentures, LLC | Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents |
| EP3177144A4 (en) | 2014-07-22 | 2018-01-24 | Bioventures, LLC. | Compositions and methods for selectively depleting senescent cells |
| CN104163798A (zh) * | 2014-07-29 | 2014-11-26 | 苏州康润医药有限公司 | 3-氨基-8-三氟甲基喹啉的合成方法 |
| LT3179991T (lt) | 2014-08-11 | 2021-11-10 | Acerta Pharma B.V. | Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai |
| IL313498A (en) | 2014-10-06 | 2024-08-01 | Vertex Pharma | Modulators of the cystic fibrosis transmembrane conductance regulator |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| LT3319995T (lt) | 2015-07-07 | 2019-07-10 | F. Hoffmann-La Roche Ag | Sudėtinis gydymas anti-her-2 antikūno-vaisto konjugatu ir bcl-2 inhibitoriumi |
| WO2017063572A1 (zh) * | 2015-10-13 | 2017-04-20 | 苏州晶云药物科技有限公司 | 细胞凋亡诱导剂的新晶型及其制备方法 |
| CN108367006B (zh) | 2015-12-04 | 2021-12-31 | 博尔托拉制药公司 | 用于治疗血液癌症的赛度替尼 |
| US11001582B2 (en) | 2016-03-10 | 2021-05-11 | Assia Chemical Industries Ltd. | Solid state forms of Venetoclax and processes for preparation of Venetoclax |
| EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| US11013698B2 (en) | 2016-03-15 | 2021-05-25 | Oryzon Genomics S.A. | Combinations of LSD1 inhibitors for the treatment of hematological malignancies |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3445452A4 (en) | 2016-04-21 | 2019-10-30 | BioVentures, LLC | COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF |
| KR102429704B1 (ko) * | 2016-08-05 | 2022-08-04 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| CN109641897B (zh) * | 2016-09-01 | 2021-12-07 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
| HRP20211683T1 (hr) | 2016-09-30 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora |
| CN106749233B (zh) * | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
| RS64976B1 (sr) | 2016-12-01 | 2024-01-31 | Arvinas Operations Inc | Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| WO2018127130A1 (en) * | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| JOP20190191A1 (ar) | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| WO2018167652A1 (en) * | 2017-03-13 | 2018-09-20 | Laurus Labs Limited | Process for preparation of amorphous form of venetoclax |
| CN110546151B (zh) * | 2017-04-18 | 2023-04-28 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
| CN107089981A (zh) * | 2017-04-24 | 2017-08-25 | 杭州科耀医药科技有限公司 | 一种BCL‑2抑制剂Venetoclax的合成方法 |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| ES3028360T3 (en) * | 2017-06-26 | 2025-06-19 | Shenzhen Targetrx Inc | Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| JP2020528061A (ja) | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法 |
| EP3658188A1 (en) | 2017-07-26 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Combination therapy with a bet inhibitor and a bcl-2 inhibitor |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| EP3672975B1 (en) | 2017-08-23 | 2023-04-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Condensed heterocyclic derivatives as bcl-2 inhibitors for the treatment of neoplastic diseases |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| CN108037196B (zh) * | 2017-11-23 | 2020-06-23 | 中山奕安泰医药科技有限公司 | 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法 |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| SG11202005985PA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| CN112105360B (zh) | 2018-01-22 | 2024-01-30 | 生物风险投资有限责任公司 | 用于癌症治疗的bcl-2蛋白降解剂 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| CA3090177A1 (en) | 2018-02-16 | 2019-08-22 | Abbvie Inc. | Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| CN114369094B (zh) * | 2018-03-30 | 2023-09-29 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 |
| WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| FI3788042T3 (fi) * | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| JP7324778B2 (ja) | 2018-05-04 | 2023-08-10 | ポートラ ファーマシューティカルズ， エルエルシー | セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| WO2020023435A1 (en) | 2018-07-24 | 2020-01-30 | Albany Molecular Research, Inc. | Venetoclax basic salts and processes for the purification of venetoclax |
| TW202023568A (zh) | 2018-07-30 | 2020-07-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| US11554127B2 (en) | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| EP3672594B1 (en) | 2018-07-31 | 2021-09-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| WO2020041406A1 (en) | 2018-08-22 | 2020-02-27 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| CA3117849A1 (en) * | 2018-10-29 | 2020-05-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor |
| CN109438441A (zh) * | 2018-11-30 | 2019-03-08 | 重庆三圣实业股份有限公司 | 一种维奈妥拉的制备方法及其产品 |
| CN109320516A (zh) * | 2018-11-30 | 2019-02-12 | 重庆三圣实业股份有限公司 | 一种维奈妥拉中间体的制备方法及其产品 |
| WO2020232214A1 (en) | 2019-05-14 | 2020-11-19 | Abbvie Inc. | Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor |
| WO2020234445A1 (en) | 2019-05-23 | 2020-11-26 | F. Hoffmann-La Roche Ag | Combination therapy with a bet inhibitor and a bcl-2 inhibitor |
| EP3978494A4 (en) * | 2019-05-24 | 2023-04-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | METHYL AND TRFLUOROMETHYL CONTAINING DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITORS |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| WO2021037933A1 (en) | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
| CN112661751B (zh) * | 2019-10-16 | 2024-06-14 | 南京天印健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| EP4051676A4 (en) * | 2019-10-28 | 2023-11-22 | BeiGene, Ltd. | BCL-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| TW202200574A (zh) | 2020-04-15 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Bcl-2抑制劑 |
| TWI896655B (zh) * | 2020-04-29 | 2025-09-11 | 大陸商正大天晴藥業集團股份有限公司 | 三氟甲基和氯雙取代的磺醯胺類選擇性bcl-2抑制劑的晶體 |
| CN111848607B (zh) * | 2020-07-22 | 2023-03-17 | 长沙创新药物工业技术研究院有限公司 | 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途 |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| US20230398110A1 (en) * | 2020-08-21 | 2023-12-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| CN114478520B (zh) * | 2020-10-28 | 2025-01-10 | 杭州和正医药有限公司 | Bcl-2蛋白凋亡诱导剂及应用 |
| CN114736203A (zh) * | 2021-01-07 | 2022-07-12 | 南京天印健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| CA3211639A1 (en) | 2021-03-19 | 2022-09-22 | Volodymyr KYSIL | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors |
| WO2022218311A1 (en) * | 2021-04-13 | 2022-10-20 | Appicine Therapeutics (Hk) Limited | Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof |
| EP4353722A4 (en) | 2021-06-04 | 2025-06-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phosphate of trifluoromethyl-substituted sulfonamide compound |
| MX2024002465A (es) * | 2021-08-31 | 2024-04-29 | Beigene Ltd | Formas solidas de inhibidores de bcl-2, metodo de preparacion y sus usos. |
| IT202100025976A1 (it) | 2021-10-06 | 2023-04-06 | Univ Degli Studi Di Perugia | Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1) |
| US20250154141A1 (en) | 2021-12-09 | 2025-05-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
| WO2024012557A1 (en) * | 2022-07-15 | 2024-01-18 | Berrybio (Hong Kong) Limited | Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications |
| KR20250079128A (ko) * | 2022-07-21 | 2025-06-04 | 베이진 스위찰랜드 게엠베하 | Bcl-2 저해제를 사용한 다발성 골수종의 치료 방법 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
| KR102598137B1 (ko) | 2022-11-24 | 2023-11-06 | 율촌화학 주식회사 | 고차단성 생분해 필름 및 이의 제조방법 |
| EP4421075A1 (en) | 2023-02-27 | 2024-08-28 | KRKA, d.d., Novo mesto | Process for the preparation of venetoclax and intermediates used therein |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2579596B1 (fr) * | 1985-03-26 | 1987-11-20 | Inst Nat Sante Rech Med | (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique |
| CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
| CA2016710A1 (en) * | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
| GB9110625D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| ATE234270T1 (de) * | 1992-12-02 | 2003-03-15 | Pfizer | Cathecoldiether als selektive pde iv hemmungsmittel |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| WO1999018099A1 (en) * | 1997-10-03 | 1999-04-15 | Merck Frosst Canada & Co. | Aryl thiophene derivatives as pde iv inhibitors |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| CN1149196C (zh) * | 1998-07-06 | 2004-05-12 | 布里斯托尔-迈尔斯斯奎布公司 | 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺 |
| DE19830430A1 (de) * | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| KR100641802B1 (ko) * | 1999-12-28 | 2006-11-02 | 에자이 가부시키가이샤 | 술폰아미드 함유 복소환 화합물 |
| GB2361003A (en) * | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2002098848A1 (en) | 2001-06-06 | 2002-12-12 | Eli Lilly And Company | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents |
| US20030059489A1 (en) | 2001-09-24 | 2003-03-27 | Canolio Inc. | Genital lubricating compositions and uses thereof |
| US20030134853A1 (en) * | 2001-09-26 | 2003-07-17 | Priestley Eldon Scott | Compounds useful for treating hepatitis C virus |
| FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| GB0215650D0 (en) * | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
| US6995787B2 (en) | 2002-08-21 | 2006-02-07 | Adams Steven L | Sports projectile and camera apparatus |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7642260B2 (en) * | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
| PL1768966T3 (pl) * | 2004-06-17 | 2012-08-31 | Infinity Discovery Inc | Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi |
| DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
| US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| KR101533268B1 (ko) * | 2005-05-12 | 2015-07-03 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
| US8624027B2 (en) * | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| CN101218241B (zh) * | 2005-05-16 | 2011-02-16 | Irm责任有限公司 | 用作蛋白激酶抑制剂的吡咯并吡啶衍生物 |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US20070115787A1 (en) * | 2005-11-23 | 2007-05-24 | Seagate Technology Llc | Planar optical device for generating optical nanojets |
| JP5277168B2 (ja) * | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| US20080182845A1 (en) * | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| EP2121641B1 (en) | 2007-02-15 | 2014-09-24 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands |
| US8536157B2 (en) | 2007-04-13 | 2013-09-17 | The University Of Melbourne | Non-steroidal compounds |
| US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| US20090131363A1 (en) | 2007-10-26 | 2009-05-21 | Harbeson Scott L | Deuterated darunavir |
| US8168784B2 (en) * | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8557983B2 (en) * | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) * | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| EP2376480B1 (en) | 2008-12-05 | 2016-06-01 | AbbVie Inc. | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) * | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US20110245156A1 (en) | 2008-12-09 | 2011-10-06 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
| US20120094963A1 (en) | 2008-12-23 | 2012-04-19 | of Queen Elizabeth near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
| CN104945311A (zh) * | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| ES2536090T3 (es) * | 2009-01-19 | 2015-05-20 | Abbvie Inc. | Agentes inductores de la apoptosis para el tratamiento del cáncer y enfermedades inmunitarias y autoinmunitarias |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| BR122019016429B1 (pt) * | 2009-05-26 | 2020-03-24 | Abbvie Ireland Unlimited Company | Compostos inibidores da atividade de proteínas bcl-2 antiapoptótica e composição farmacêutica compreendendo ditos compostos |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
-
2010
- 2010-05-26 BR BR122019016429-0A patent/BR122019016429B1/pt active IP Right Grant
- 2010-05-26 CA CA3052016A patent/CA3052016A1/en not_active Abandoned
- 2010-05-26 BR BRPI1014359-9A patent/BRPI1014359B1/pt active IP Right Grant
- 2010-05-26 IL IL299019A patent/IL299019A/en unknown
- 2010-05-26 CN CN201910261444.3A patent/CN109897038B/zh active Active
- 2010-05-26 CR CR20170019A patent/CR20170019A/es unknown
- 2010-05-26 KR KR1020237028352A patent/KR20230128571A/ko active Pending
- 2010-05-26 MX MX2011012257A patent/MX339469B/es active IP Right Grant
- 2010-05-26 KR KR1020177008201A patent/KR20170037683A/ko not_active Abandoned
- 2010-05-26 DK DK10721246.6T patent/DK2435432T6/da active
- 2010-05-26 ME MEP-2015-124A patent/ME02205B/me unknown
- 2010-05-26 RS RS20150592A patent/RS54234B2/sr unknown
- 2010-05-26 CA CA3206963A patent/CA3206963A1/en active Pending
- 2010-05-26 PT PT107212466T patent/PT2435432E/pt unknown
- 2010-05-26 RU RU2011152973A patent/RU2535347C3/ru active Protection Beyond IP Right Term
- 2010-05-26 AR ARP100101806A patent/AR076705A1/es active IP Right Grant
- 2010-05-26 EP EP24195253.0A patent/EP4474383A3/en active Pending
- 2010-05-26 EP EP15167892.7A patent/EP2944638A1/en not_active Withdrawn
- 2010-05-26 PH PH1/2015/500297A patent/PH12015500297B1/en unknown
- 2010-05-26 JP JP2012513209A patent/JP5747025B2/ja active Active
- 2010-05-26 PE PE2011002025A patent/PE20120345A1/es active IP Right Grant
- 2010-05-26 ES ES10721246T patent/ES2546294T7/es active Active
- 2010-05-26 KR KR1020157014221A patent/KR101723378B1/ko active Active
- 2010-05-26 IL IL319747A patent/IL319747A/en unknown
- 2010-05-26 CA CA2929347A patent/CA2929347A1/en not_active Abandoned
- 2010-05-26 UY UY0001032668A patent/UY32668A/es active IP Right Grant
- 2010-05-26 KR KR1020197020313A patent/KR20190086591A/ko not_active Abandoned
- 2010-05-26 EP EP10721246.6A patent/EP2435432B3/en active Active
- 2010-05-26 CN CN201510165051.4A patent/CN104876927B/zh active Active
- 2010-05-26 PL PL10721246.6T patent/PL2435432T6/pl unknown
- 2010-05-26 SI SI201031011T patent/SI2435432T2/sl unknown
- 2010-05-26 KR KR1020117030916A patent/KR101659583B1/ko active Active
- 2010-05-26 NZ NZ595708A patent/NZ595708A/en unknown
- 2010-05-26 HR HRP20151001TT patent/HRP20151001T4/hr unknown
- 2010-05-26 KR KR1020187032920A patent/KR102001418B1/ko active Active
- 2010-05-26 KR KR1020197033737A patent/KR20190130676A/ko active Pending
- 2010-05-26 TW TW103138402A patent/TWI537269B/zh active
- 2010-05-26 MY MYPI2011005633A patent/MY155645A/en unknown
- 2010-05-26 CA CA2759182A patent/CA2759182C/en active Active
- 2010-05-26 CN CN201910270919.5A patent/CN109966294A/zh active Pending
- 2010-05-26 UA UAA201115309A patent/UA106079C2/uk unknown
- 2010-05-26 KR KR1020187011857A patent/KR101920202B1/ko active Active
- 2010-05-26 EP EP19195104.5A patent/EP3656771A1/en not_active Withdrawn
- 2010-05-26 SG SG10201704742YA patent/SG10201704742YA/en unknown
- 2010-05-26 AU AU2010254160A patent/AU2010254160C1/en active Active
- 2010-05-26 TW TW099116922A patent/TWI476195B/zh active
- 2010-05-26 RU RU2014132884/04A patent/RU2573832C2/ru active
- 2010-05-26 TW TW104138114A patent/TWI561523B/zh active
- 2010-05-26 CN CN201510215766.6A patent/CN104906100A/zh active Pending
- 2010-05-26 CN CN201080023068.1A patent/CN102448959B/zh active Active
- 2010-05-26 HU HUE10721246A patent/HUE027698T2/en unknown
- 2010-05-26 SG SG2011075843A patent/SG175253A1/en unknown
- 2010-05-26 WO PCT/US2010/036198 patent/WO2010138588A2/en not_active Ceased
- 2010-11-22 US US12/951,344 patent/US8580794B2/en active Active
- 2010-11-23 UY UY0001033047A patent/UY33047A/es not_active Application Discontinuation
-
2011
- 2011-10-09 IL IL215644A patent/IL215644A/en active IP Right Grant
- 2011-11-17 MX MX2019012154A patent/MX2019012154A/es unknown
- 2011-11-22 CL CL2011002949A patent/CL2011002949A1/es unknown
- 2011-11-23 ZA ZA2011/08616A patent/ZA201108616B/en unknown
- 2011-11-25 CR CR20110632A patent/CR20110632A/es unknown
- 2011-11-25 DO DO2011000367A patent/DOP2011000367A/es unknown
- 2011-12-26 CO CO11178424A patent/CO6480950A2/es not_active Application Discontinuation
- 2011-12-26 EC EC2011011554A patent/ECSP11011554A/es unknown
-
2015
- 2015-01-09 JP JP2015003098A patent/JP6038195B2/ja active Active
- 2015-09-23 CY CY20151100832T patent/CY1117423T1/el unknown
- 2015-09-24 SM SM201500225T patent/SMT201500225B/xx unknown
- 2015-12-18 RU RU2015154494A patent/RU2628885C2/ru active
-
2016
- 2016-03-25 HK HK16103532.1A patent/HK1215576A1/en unknown
- 2016-10-31 JP JP2016212548A patent/JP6353506B2/ja active Active
-
2017
- 2017-05-16 NL NL300873C patent/NL300873I2/nl unknown
- 2017-05-16 HU HUS1700021C patent/HUS1700021I1/hu unknown
- 2017-05-18 LT LTPA2017015C patent/LTC2435432I2/lt unknown
- 2017-05-25 CY CY2017019C patent/CY2017019I1/el unknown
- 2017-05-29 NO NO2017023C patent/NO2017023I1/no unknown
- 2017-05-29 FI FIEP10721246.6T patent/FI2435432T6/fi active
- 2017-08-07 IL IL253891A patent/IL253891A0/en unknown
- 2017-10-18 AR ARP170102895A patent/AR109974A2/es active IP Right Grant
-
2018
- 2018-04-18 JP JP2018079598A patent/JP2018138577A/ja not_active Ceased
- 2018-07-31 UY UY0001037825A patent/UY37825A/es active IP Right Grant
-
2019
- 2019-09-03 IL IL26909219A patent/IL269092A/en unknown
- 2019-10-17 JP JP2019189974A patent/JP2020023545A/ja not_active Ceased
-
2021
- 2021-09-01 IL IL286036A patent/IL286036A/en unknown
- 2021-12-09 JP JP2021199837A patent/JP2022033939A/ja not_active Ceased
-
2023
- 2023-01-10 JP JP2023001499A patent/JP2023040165A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019817A patent/JP2025072583A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528178A5 (OSRAM) | ||
| RU2011152973A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний | |
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| JP2017048219A5 (OSRAM) | ||
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2016517406A5 (OSRAM) | ||
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| RU2018127315A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний | |
| JP6884528B2 (ja) | 癌および骨癌疼痛の治療方法 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| JP2013512900A5 (OSRAM) | ||
| JP2017530999A5 (OSRAM) | ||
| JP2017537948A5 (OSRAM) | ||
| JP2013512899A5 (OSRAM) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2013528204A5 (OSRAM) | ||
| JP2014530237A5 (OSRAM) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2012127790A (ru) | Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2008513514A5 (OSRAM) | ||
| JP2016526540A5 (OSRAM) | ||
| JP2019537571A5 (OSRAM) | ||
| RU2012156940A (ru) | Лекарственные средства, индуцирующие апоптоз, для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2014523851A5 (OSRAM) | ||
| JP2019505595A5 (OSRAM) |